Sarepta Therapeutics Down Over 45%, on Track for Lowest Close Since June 2016 -- Data Talk

Dow Jones
Jun 16, 2025

Sarepta Therapeutics, Inc. (SRPT) is currently at $19.84, down $16.34 or 45.16%

 

--Would be lowest close since June 30, 2016, when it closed at $19.07

--On pace for largest percent decrease since Jan. 8, 2021, when it fell 51.29%

--Currently down seven of the past eight days

--Currently down six consecutive days; down 53.87% over this period

--Longest losing streak since April 1, 2025, when it fell for six straight trading days

--Worst six day stretch since the six days ending Jan. 25, 2016, when it fell 61.81%

--Down 47.23% month-to-date

--Down 83.68% year-to-date

--Down 88.9% from its all-time closing high of $178.74 on Dec. 22, 2020

--Down 83.02% from 52 weeks ago (June 17, 2024), when it closed at $116.83

--Down 87.89% from its 52-week closing high of $163.85 on June 24, 2024

--Would be a new 52-week closing low

--Traded as low as $18.30; lowest intraday level since June 30, 2016, when it hit $18.29

--Down 49.42% at today's intraday low; largest intraday percent decrease since Jan. 8, 2021, when it fell as much as 51.32%

 

All data as of 10:44:56 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

June 16, 2025 10:48 ET (14:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10